PortalPublikationenPlasma DNA integrity as a biomarker for primary and metastat...

Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis

Standard

Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. / Madhavan, Dharanija; Wallwiener, Markus; Bents, Karin; Zucknick, Manuela; Nees, Juliane; Schott, Sarah; Cuk, Katarina; Riethdorf, Sabine; Trumpp, Andreas; Pantel, Klaus; Sohn, Christof; Schneeweiss, Andreas; Surowy, Harald; Burwinkel, Barbara.

in: BREAST CANCER RES TR, Jahrgang 146, Nr. 1, 01.07.2014, S. 163-174.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Madhavan, D, Wallwiener, M, Bents, K, Zucknick, M, Nees, J, Schott, S, Cuk, K, Riethdorf, S, Trumpp, A, Pantel, K, Sohn, C, Schneeweiss, A, Surowy, H & Burwinkel, B 2014, 'Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis', BREAST CANCER RES TR, Jg. 146, Nr. 1, S. 163-174. https://doi.org/10.1007/s10549-014-2946-2

APA

Madhavan, D., Wallwiener, M., Bents, K., Zucknick, M., Nees, J., Schott, S., Cuk, K., Riethdorf, S., Trumpp, A., Pantel, K., Sohn, C., Schneeweiss, A., Surowy, H., & Burwinkel, B. (2014). Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. BREAST CANCER RES TR, 146(1), 163-174. https://doi.org/10.1007/s10549-014-2946-2

Vancouver

Madhavan D, Wallwiener M, Bents K, Zucknick M, Nees J, Schott S et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. BREAST CANCER RES TR. 2014 Jul 1;146(1):163-174. https://doi.org/10.1007/s10549-014-2946-2

Bibtex

@article{4e7241b4a6d843a6b80fdd815ff83cf5,
title = "Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis",
abstract = "Circulating or cell-free DNA (cfDNA) has been evaluated as a biomarker in many cancers including breast cancer. In particular, integrity of cfDNA has been shown to be altered in cancers. We have estimated the biomarker potential of cfDNA in primary (PBC) and metastatic breast cancer (MBC). cfDNA integrity (cfDI) and concentration were determined in plasma of 383 individuals, including 82 PBC and 201 MBC cases, as well as 100 healthy controls, by measuring ALU and LINE1 repetitive DNA elements using quantitative PCR. The MBC patient group was further sub-divided into patients with detectable circulating tumour cells (CTCpos-MBC, n = 100) and those without (CTCneg-MBC, n = 101). A hierarchical decrease in cfDI and increase in cfDNA concentration from healthy controls to PBC and further onto MBC patients were observed. Investigation of cfDNA in media of cell lines was in concordance with these results. Combination of cfDI and cfDNA concentration could differentiate PBC cases from controls (area under the curve, AUC = 0.75), MBC cases from controls (AUC = 0.81 for CTCneg-MBC, AUC = 0.93 for CTCpos-MBC), and CTCneg-MBC from CTCpos-MBC cases (AUC = 0.83). cfDI additionally demonstrated a positive correlation to progression-free (HR of 0.46 for ALU, P = 0.0025) and overall survival (HR of 0.15 for ALU and 0.20 for LINE1, P < 0.0001) in MBC, and had lower prediction error than CTC status. Our findings show that reduced cfDI and increased cfDNA concentration can serve as diagnostic markers for PBC and MBC, and cfDI as a prognostic marker for MBC, thereby making them attractive candidates for blood-based multi-marker assays.",
author = "Dharanija Madhavan and Markus Wallwiener and Karin Bents and Manuela Zucknick and Juliane Nees and Sarah Schott and Katarina Cuk and Sabine Riethdorf and Andreas Trumpp and Klaus Pantel and Christof Sohn and Andreas Schneeweiss and Harald Surowy and Barbara Burwinkel",
year = "2014",
month = jul,
day = "1",
doi = "10.1007/s10549-014-2946-2",
language = "English",
volume = "146",
pages = "163--174",
journal = "BREAST CANCER RES TR",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

RIS

TY - JOUR

T1 - Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis

AU - Madhavan, Dharanija

AU - Wallwiener, Markus

AU - Bents, Karin

AU - Zucknick, Manuela

AU - Nees, Juliane

AU - Schott, Sarah

AU - Cuk, Katarina

AU - Riethdorf, Sabine

AU - Trumpp, Andreas

AU - Pantel, Klaus

AU - Sohn, Christof

AU - Schneeweiss, Andreas

AU - Surowy, Harald

AU - Burwinkel, Barbara

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Circulating or cell-free DNA (cfDNA) has been evaluated as a biomarker in many cancers including breast cancer. In particular, integrity of cfDNA has been shown to be altered in cancers. We have estimated the biomarker potential of cfDNA in primary (PBC) and metastatic breast cancer (MBC). cfDNA integrity (cfDI) and concentration were determined in plasma of 383 individuals, including 82 PBC and 201 MBC cases, as well as 100 healthy controls, by measuring ALU and LINE1 repetitive DNA elements using quantitative PCR. The MBC patient group was further sub-divided into patients with detectable circulating tumour cells (CTCpos-MBC, n = 100) and those without (CTCneg-MBC, n = 101). A hierarchical decrease in cfDI and increase in cfDNA concentration from healthy controls to PBC and further onto MBC patients were observed. Investigation of cfDNA in media of cell lines was in concordance with these results. Combination of cfDI and cfDNA concentration could differentiate PBC cases from controls (area under the curve, AUC = 0.75), MBC cases from controls (AUC = 0.81 for CTCneg-MBC, AUC = 0.93 for CTCpos-MBC), and CTCneg-MBC from CTCpos-MBC cases (AUC = 0.83). cfDI additionally demonstrated a positive correlation to progression-free (HR of 0.46 for ALU, P = 0.0025) and overall survival (HR of 0.15 for ALU and 0.20 for LINE1, P < 0.0001) in MBC, and had lower prediction error than CTC status. Our findings show that reduced cfDI and increased cfDNA concentration can serve as diagnostic markers for PBC and MBC, and cfDI as a prognostic marker for MBC, thereby making them attractive candidates for blood-based multi-marker assays.

AB - Circulating or cell-free DNA (cfDNA) has been evaluated as a biomarker in many cancers including breast cancer. In particular, integrity of cfDNA has been shown to be altered in cancers. We have estimated the biomarker potential of cfDNA in primary (PBC) and metastatic breast cancer (MBC). cfDNA integrity (cfDI) and concentration were determined in plasma of 383 individuals, including 82 PBC and 201 MBC cases, as well as 100 healthy controls, by measuring ALU and LINE1 repetitive DNA elements using quantitative PCR. The MBC patient group was further sub-divided into patients with detectable circulating tumour cells (CTCpos-MBC, n = 100) and those without (CTCneg-MBC, n = 101). A hierarchical decrease in cfDI and increase in cfDNA concentration from healthy controls to PBC and further onto MBC patients were observed. Investigation of cfDNA in media of cell lines was in concordance with these results. Combination of cfDI and cfDNA concentration could differentiate PBC cases from controls (area under the curve, AUC = 0.75), MBC cases from controls (AUC = 0.81 for CTCneg-MBC, AUC = 0.93 for CTCpos-MBC), and CTCneg-MBC from CTCpos-MBC cases (AUC = 0.83). cfDI additionally demonstrated a positive correlation to progression-free (HR of 0.46 for ALU, P = 0.0025) and overall survival (HR of 0.15 for ALU and 0.20 for LINE1, P < 0.0001) in MBC, and had lower prediction error than CTC status. Our findings show that reduced cfDI and increased cfDNA concentration can serve as diagnostic markers for PBC and MBC, and cfDI as a prognostic marker for MBC, thereby making them attractive candidates for blood-based multi-marker assays.

U2 - 10.1007/s10549-014-2946-2

DO - 10.1007/s10549-014-2946-2

M3 - SCORING: Journal article

C2 - 24838941

VL - 146

SP - 163

EP - 174

JO - BREAST CANCER RES TR

JF - BREAST CANCER RES TR

SN - 0167-6806

IS - 1

ER -